Technology Transfer News

Datum
With its AI platform, InterAx is setting new standards in drug development.

InterAx Biotech revolutionises drug development with new modes of action

InterAx Biotech AG, a spin-off company of the Paul Scherrer Institute and ETH, is setting new standards in drug development with its advanced AI platform. By uncovering novel cellular signalling pathways, the company is paving the way for innovative therapies in the fields of diabetes, obesity and immuno-oncology. 

Read more
The this year's KMU Swiss Symposium will take place in Baden on 21st March (source: www.kmuswiss.ch)

PSI at the this year’s KMU Swiss Symposium!

This year's KMU Swiss Symposium will take place in Baden, Kt. Aargau, on 21 March - we are pleased to be there again this year!

The KMU Swiss Symposium offers a platform for exchange and inspiration - this is made possible by exciting presentations, various booths with innovative projects and networking.

Listen to exciting presentations on the topic of ""AI / digital leads to a better world - or is it just a game changer?"" by, among others, Dr. Urs Rickenbacher, CEO Lantal Textiles AG, Sabrina Schenardi, co-founder of BLP Digital, or Matthias Mölleney, owner of peopleXpert GmbH.

PSI will be there - visit us at our joint booth with the Hightech Zentrum Aargau!

Find out more about how we can support industry and SMEs with their technical challenges and innovation processes.

Detailed information and registration for the event at:

https://www.kmuswiss.ch/de/events/event-details/124/2024-kmu-swiss-symposium-baden-ki-digital-fuehrt-zu-besserer-welt-oder-ist-nur-ein-gamechanger.html

Read more
SIF 2023 will take place in the Congress Center in Basel on 30 November 2023 (image source: Swiss Innovation Forum).

PSI at the this year's Swiss Innovation Forum!

Networking and exchange, inspiration and new ways of thinking can make an important contribution to innovation. That’s why we as PSI support the this year’s edition of the Swiss Innovation Forum (SIF) 2023 in Basel as a partner.

On 30 November, motivated start-ups, committed investors and courageous idea generators meet at the Congress Centre Basel. In a cross-sector exchange, they develop new ideas to drive the Swiss innovation landscape forward.

Highlights of the programme:

💡 Keynotes by Catrin Hinkel (CEO, Microsoft Schweiz), Jürgen Geuter (Tech De-Evangelist & Co-Founder, Otherwise Network), Prof. Dr. Gregor Hasler (Professor, Chefarzt, Universität Freiburg und Freiburger Netzwerk für Psychische Gesundheit (Schweiz)) and many more.

💡 Presentation of the Swiss Technology Award 2023, the most important technology prize in Switzerland.

💡 Experience Zone with exciting cases from Switzerland as a country of innovation.

PSI will be there: Together with ETH Zurich, we will be presenting the exciting topic of "Quantum Computing" at our stand at FutureExpo this year! Looking forward to meeting you there!

Detailed information and registration for the conference at www.swiss-innovation.com/en/

Read more
Technology Briefing: The Journey through Energy Storage Technologies

Technology Briefing: The Journey through Energy Storage Technologies

Our next Technology Briefing on Energy Storage Technologies will be held at CSEM in Neuchatel on 16 November 2023.

Join us for the upcoming Technology Briefing on Switzerland’s Climate Neutrality 2050: The Journey through Energy Storage Technologies. The conference is presented jointly by CSEM, Empa and PSI. This is a unique opportunity to learn from the leading experts in the field and network with other professionals from the industrial, sustainable energy, digital energy, digital grid sectors, and more.

When: November 16, 2023; 13:30 – 18:00h

Where: Auditorium EPFL, Rue de la Maladière 71C, 2002 Neuchâtel  

In this Technology Briefing, you will discover the latest developments and challenges in energy storage technologies, and how they can contribute to Switzerland’s climate neutrality by 2050. You will also hear from experts who are working on cutting-edge research projects in this field.

We look forward to having a lively and fruitful exchange with you!

Participation in the event is free of charge - registration is required. We look forward to meeting you in Neuchatel!

You can find more details and the registration form at:

https://www.csem.ch/de/veranstaltungen/switzerlands-climate-neutrality-2050-the-journey-through-energy-storage-technologies

Read more
Seminar "Diffraction for Industrial Applications": Learn how ANAXAM can help your business!

Industry Seminar ANAXAM: "Neutron and Synchrotron X-ray Diffraction for Industrial Applications"

The technology transfer centre ANAXAM offers industry access to analytical methods with neutron and synchrotron radiation and supports its industrial customers in being able to offer innovative and high-quality products. SMEs in particular benefit from ANAXAM and can thereby strengthen their competitiveness.

ANAXAM has already helped numerous customers to improve their production processes and products.

The seminar "Introduction to Neutron and Synchrotron X-ray Diffraction for Industrial Applications" aims to introduce the basic principles of Diffraction and how Diffraction analytics using Neutrons and Synchrotron X-rays facilitate investigating industrial materials.

Benefit from ANAXAM's know-how and competences and learn how to take your company a step forward with ANAXAM.

WHEN: 22 November 2023; 2:00 - 3:30 p.m.

The seminar takes place online and is free of charge.

More information and link to register:

https://www.anaxam.ch/de/events/introduction-neutron-and-synchrotron-x-ray-diffraction-industrial-applications 

The language of the seminar is English.

Read more
Araris made it to TOP14 in this year's edition of the TOP 100 Swiss Startup Award (source: https://www.top100startups.swiss/).

TOP 100 Swiss Startup Award: Araris Biotech AG ranks TOP 14!

Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on the commercialization of a novel antibody-drug conjugate (ADC)-linker technology.

At the this year’s edition of the TOP 100 Swiss Startup Award, where Switzerland’s best startups with the greatest potential are celebrated, Araris ranks TOP14!

It is now the fifth year in a row, starting 2019, that Araris is selected by a Jury of investors and startup experts.

What a great success for Araris, after positions 19 in 2022 and 11 in 2021. 

We congratulate Philipp Spycher (CEO) and his team for this great achievement!

Read more
Seminar "Imaging for Industrial Applications": Learn how ANAXAM can help your business!

ANAXAM Industry Seminar: "Neutron and Synchrotron Imaging for Industrial Applications"

 

The Technology Transfer Centre ANAXAM offers industry access to analytical methods with neutron and synchrotron radiation and supports its industrial customers in being able to offer innovative and high-quality products.

The seminar "Introduction to Neutron and Synchrotron Imaging for Industrial Applications" aims to introduce the basic principles of imaging and to show how imaging analytics with neutron and synchrotron radiation facilitates the investigation of industrial materials.

Benefit from ANAXAM's know-how and competences and learn how to take your company a step forward with ANAXAM!

WHEN: 15 November 2023; 2:00 - 3:30 p.m.

The seminar takes place online and is free of charge.

More information and link to register:

https://www.anaxam.ch/de/events/introduction-neutron-and-synchrotron-x-...

The language of the seminar is English.

Read more
Michal Rawlik (left), first author of the publication, and Marco Stampanoni hope to be able to decisively improve breast cancer diagnostics with the new method. (Photo: Paul Scherrer Institute/Markus Fischer)

Earlier detection of breast cancer

Promising method for diagnosing breast cancer: a research team from PSI, ETH Zurich, the Cantonal Hospital Baden and the University Hospital Zurich has further developed and improved the method for the early detection of breast cancer and promises hope for diagnostics.

Breast cancer is still the most common type of cancer in women today. In the course of her life, one in nine women is affected. In Switzerland alone, about 6000 women are diagnosed with breast cancer every year. This means that this type of cancer accounts for about one third of all cancer diagnoses in women.

The mammography used up to now only provides two-dimensional images, which often leads to unclear or incorrect diagnoses. The improved procedure based on X-ray phase contrast should not only provide considerably more reliable results, but will also be less painful for patients. Tumours should now be detected earlier than before due to the three-dimensional representation of the images, which in turn means that appropriate therapy can be started earlier and valuable time can be gained.

The research team plans to start clinical trials by the end of 2024, as soon as the prototype of the necessary device is ready for use. A project duration of one to two years is planned for the test series that will then follow, until the development of a commercial device could begin.

More information can be found here:

Read more

Promising collaboration with ITM in the field of cancer therapy

PSI and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, have entered into a collaboration for the joint development of the production of a novel therapeutic radionuclide, terbium-161. In this collaboration, PSI and ITM will combine their respective technologies and expertise in the production of terbium-161, including clinical and commercial use in targeted radionuclide therapy for the treatment of cancer. The goal is to be able to offer cancer patients new and better treatment options.

Terbium-161 has been identified as a very promising therapeutic isotope for targeted radionuclide therapy in cancer due to its excellent physicochemical properties: The convincing therapeutic capabilities of terbium-161 have been demonstrated in various preclinical studies at PSI. The collaboration with ITM - a pioneer and major player in the field of radiopharmaceutical applications - aims to combine PSI's long-standing research with ITM's extensive knowledge to drive further innovation in radionuclide therapy.

With this collaboration, ITM expands its research and production portfolio alongside Lutetium-177 and Actinium-225, which are currently the most widely used medical radioisotopes for targeted radionuclide therapy and which ITM supplies to hospitals and pharmaceutical partners worldwide.

Read more